- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1744 |
Product Name |
ADT1744-Human Anti-VEGFAxANGPT2 Bispecific Antibody |
Isotype |
Human IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-VEGFA mAb, Anti-VEGFA Monoclonal Antibody, VEGFA recombinant antibody, Anti-VEGFA Bispecific Antibody, Human Anti-ANGPT2 mAb, ANGPT2 recombinant antibody, Anti-ANGPT2 Monoclonal Antibody, Anti-ANGPT2 Bispecific Antibody |
|
Official Symbol |
VEGFAxANGPT2 |
Target 1 |
VEGFA |
Gene ID 1 |
7422 |
Target 2 |
ANGPT2 |
Gene ID 2 |
285 |
Species |
Human |
Drug Name |
Faricimab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
1607793-29-2 |
Chemical Formula |
C6506H9968N1724O1026S45 |
Molecular Weight |
149 KDa |
Product Description |
Faricimab is an IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema. |
Mechanism of Action |
Faricimab is a bispecific antibody (bsAb) based on human IgG1 comprising two different heavy and two different light chains capable of simultaneously binding to both VEGF-A and Ang-2 produced using the "CrossMab" platform. Faricimab binds VEGF-A and Ang-2 with binding affinities (KD) of approximately 3 and 22 nM, respectively; importantly, faricimab does not detectably bind Ang-1. Also, the faricimab Fc region has been modified to reduce binding to FcγR and FcRn receptors. |
Metabolism |
Faricimab metabolism has not been fully characterized; as an antibody, faricimab is expected to be catabolized like endogenous immunoglobulins. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Campochiaro PA: Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015 Nov;49:67-81. doi: 10.1016/j.preteyeres.2015.06.002. Epub 2015 Jun 23.
2. Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM: Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells. 2020 Aug 10;9(8). pii: cells9081869. doi: 10.3390/cells9081869.
3. Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov.
|
FAQ
-
+ -
What roles do VEGFA and ANGPT2 play?
VEGFA drives angiogenesis, while ANGPT2 destabilizes blood vessels. Dual inhibition normalizes tumor vasculature and reduces metastasis.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
What are the applications of BsAbs?
BsAbs have been widely used in tumor immunotherapy and in the treatment of other diseases such as hemophilia A, diabetes, Alzheimer's disease, and ophthalmic diseases. -
+ -
What is the main mechanism of action of bispecific antibodies?
The main mechanisms of action of bispecific antibodies include recruiting and activating immune cells to exert killing effects, blocking dual signaling pathways, blocking immune checkpoints, and forcing protein complex association.